Last updated: August 9, 2026
Hydroxypropyl betadex, also called hydroxypropyl-beta-cyclodextrin or HPβCD, is a pharmaceutical excipient used primarily to improve the aqueous solubility, stability, and delivery of poorly soluble active pharmaceutical ingredients. Its commercial value is concentrated in injectable, oral liquid, ophthalmic, and specialty formulations rather than high-volume tablet manufacturing.
The market has durable technical demand but limited public financial transparency. Manufacturers generally report HPβCD within broader cyclodextrin, excipient, or pharmaceutical-ingredient businesses. No major supplier publicly discloses standalone HPβCD revenue, volume, or operating margin. Financial performance is therefore best assessed through formulation adoption, regulatory qualification, supply-chain position, and exposure to approved products.
What is hydroxypropyl betadex used for in pharmaceuticals?
Hydroxypropyl betadex is a chemically modified beta-cyclodextrin. Its hydrophilic hydroxypropyl substitutions improve water solubility compared with native beta-cyclodextrin and allow it to form inclusion complexes with hydrophobic drug molecules.
Key pharmaceutical functions include:
- Increasing apparent solubility of poorly water-soluble APIs
- Improving dissolution and oral absorption
- Stabilizing drug molecules against oxidation, hydrolysis, or light
- Reducing precipitation after dilution
- Supporting injectable and oral liquid dosage forms
- Masking unpleasant taste in pediatric and oral-liquid products
- Enabling reformulation of existing drugs into liquid or parenteral presentations
HPβCD is distinct from sulfobutylether-beta-cyclodextrin, commonly known as SBECD or Captisol. SBECD is used in several modern injectable products, including remdesivir and voriconazole. HPβCD is used in different products and has a separate regulatory, toxicological, and commercial profile.
Which approved drugs use hydroxypropyl betadex?
The best-known commercial application is itraconazole.
The U.S. product label for SPORANOX oral solution identifies hydroxypropyl-beta-cyclodextrin as a major inactive ingredient. The oral solution contains 10 mg of itraconazole per mL and uses HPβCD to solubilize the triazole antifungal [1]. The former intravenous formulation of itraconazole also relied on HPβCD as a solubilizing excipient.
This application demonstrates the commercial importance of HPβCD: the excipient can become necessary to deliver an API at a practical concentration when conventional surfactants, cosolvents, or lipid systems are unsuitable.
Other applications are often product-specific, regional, investigational, or proprietary. Public approval databases do not provide a complete global inventory because excipient names may be recorded under different nomenclature, including:
- Hydroxypropyl-beta-cyclodextrin
- Hydroxypropyl betadex
- Hydroxypropyl cyclodextrin
- HP-β-CD
- Hydroxypropylated beta-cyclodextrin
How large is the hydroxypropyl betadex market?
No authoritative public source reports a separately audited global market size for pharmaceutical HPβCD. Commercial market reports often combine HPβCD with native beta-cyclodextrin, SBECD, alpha-cyclodextrin, gamma-cyclodextrin, food-grade cyclodextrins, cosmetics, and industrial applications. Those aggregated figures cannot be used as a reliable measure of pharmaceutical HPβCD sales.
The pharmaceutical market is structurally smaller than the total cyclodextrin market but has higher technical barriers and generally higher value per kilogram. Demand is driven by:
- New formulation development for poorly soluble APIs.
- Lifecycle management of approved drugs.
- Injectable and pediatric dosage forms.
- Development of long-acting and localized delivery systems.
- Regulatory preference for established, compendial excipients.
- Expansion of generic and regional pharmaceutical manufacturing.
The market is likely characterized by low-to-mid single-digit volume growth in mature applications and higher potential growth in development-stage formulations. Actual revenue growth depends on whether pipeline products using HPβCD reach approval.
What drives the financial trajectory of hydroxypropyl betadex suppliers?
The financial trajectory depends less on commodity volume and more on qualification status and formulation lock-in.
Formulation lock-in
Once an excipient is incorporated into a registered formulation, replacing it can require comparative studies, stability work, process validation, and regulatory amendments. This creates recurring demand and customer retention even when the excipient represents a small percentage of finished-product cost.
Premium pharmaceutical grades
Pharmaceutical HPβCD requires control over:
- Degree of substitution
- Substitution distribution
- Residual solvents
- Water content
- Microbial quality
- Endotoxins
- Heavy metals and elemental impurities
- Residual native cyclodextrin
- Batch-to-batch molecular-weight distribution
These controls support higher pricing than food or industrial grades. Suppliers with documented GMP systems, regulatory files, global registrations, and validated analytical methods have a stronger position than low-cost producers selling non-pharmaceutical material.
Demand from poorly soluble APIs
Poor aqueous solubility remains a common development obstacle. HPβCD competes with lipid systems, surfactants, cosolvents, amorphous solid dispersions, nanocrystals, and alternative cyclodextrins. It is most commercially attractive when it solves a specific formulation problem without requiring a complex delivery platform.
Concentration limits and toxicology
High excipient loading can limit use, particularly in parenteral products. The development team must address dose, route, exposure, renal clearance, and potential accumulation. This limits HPβCD’s use in some injectable programs and creates competitive openings for SBECD, lipid formulations, or other solubilizers.
Which companies manufacture pharmaceutical hydroxypropyl betadex?
The supplier landscape includes multinational excipient companies and specialist cyclodextrin manufacturers. Publicly marketed product families include the following:
| Supplier |
Commercial positioning |
Competitive relevance |
| Roquette |
Kleptose HPB and related cyclodextrin products |
Global excipient infrastructure and pharmaceutical formulation support |
| Wacker |
CAVASOL hydroxypropyl-beta-cyclodextrin grades |
Specialty cyclodextrin manufacturing and global technical support |
| CycloLab |
Pharmaceutical cyclodextrin products and custom development |
Specialist manufacturing and formulation services |
| Regional Asian manufacturers |
HPβCD pharmaceutical and research grades |
Cost competition and regional supply diversification |
| Other specialty suppliers |
Custom or development-grade cyclodextrins |
Small-batch, analytical, and project-specific supply |
Supplier qualification is typically more important than nominal product price. A drug manufacturer must assess continuity of supply, change-control practices, documentation, pharmacopoeial compliance, audit history, and the supplier’s ability to support regulatory questions.
What regulatory status does hydroxypropyl betadex have?
HPβCD is a recognized pharmaceutical excipient, but approval is product- and route-specific. Excipients do not receive a universal FDA approval equivalent to an active drug ingredient. Their acceptability depends on prior use, specification, dose, route, and the finished product.
Relevant regulatory mechanisms include:
- FDA Inactive Ingredient Database entries
- USP-NF monographs
- European Pharmacopoeia or national pharmacopoeial standards
- Drug-master-file support
- Excipient qualification in an approved application
- Toxicology and safety data for new routes or higher exposure
The FDA Inactive Ingredient Database is a key reference for determining whether HPβCD has precedent in a particular dosage form and route [2]. The database does not eliminate the sponsor’s responsibility to justify the proposed concentration and patient exposure.
The USP-NF monograph for hydroxypropyl betadex supports identity, quality, and specification control where applicable [3]. European regulatory review also considers excipient quality, safety, function, and route-specific exposure under the European Medicines Agency’s excipient guidance [4].
What is the Orange Book status of hydroxypropyl betadex?
Hydroxypropyl betadex has no standalone Orange Book listing because it is an excipient, not an approved drug product. The Orange Book lists approved finished dosage forms and associated patents or exclusivity, not excipient ownership rights [5].
A formulation using HPβCD may be protected by patents covering:
- The active ingredient
- A specific HPβCD-to-API ratio
- A liquid or injectable composition
- A pH range
- A concentration range
- A dosing method
- A treatment method
- A manufacturing process
The excipient itself usually does not create a separate Orange Book barrier to generic entry.
What patents protect hydroxypropyl betadex formulations?
The strongest patent protection generally resides in the finished formulation rather than in the basic HPβCD molecule. Foundational beta-cyclodextrin and hydroxypropylation patents are generally old, and broad composition claims are likely to face expiration or prior-art limitations in major jurisdictions.
Current patent opportunities tend to involve narrower claims, including:
Composition patents
These may claim a specific API combined with HPβCD at defined molar ratios, concentrations, pH values, or solvent systems.
Method-of-use patents
A sponsor may claim administration of a solubilized HPβCD formulation for a disease, patient group, loading regimen, or pharmacokinetic objective.
Manufacturing patents
Claims may cover substitution control, purification, drying, complexation, sterilization, or production of a particular HPβCD grade.
Solid-state and complexation patents
A sponsor may claim a defined inclusion complex, amorphous complex, crystal form, or reconstitutable powder.
Patent strength depends on claim scope, written description, enablement, analytical distinguishability, and whether a competing manufacturer can use a different excipient or formulation ratio.
When does hydroxypropyl betadex lose exclusivity?
HPβCD itself does not have a single global exclusivity date. Exclusivity depends on the patent family, jurisdiction, claim type, and the protected product.
For finished products, generic entry is determined by the expiration of valid active-ingredient, formulation, method-of-use, and manufacturing patents, together with regulatory exclusivity. An HPβCD formulation may remain commercially differentiated after a core API patent expires if the formulation patent is enforceable. Conversely, a formulation patent may have limited practical value if a generic can use a different solubilization technology.
Paragraph IV litigation is therefore product-specific. A generic applicant can challenge a listed formulation or method-of-use patent where the relevant patent is listed in the Orange Book. A challenge to the use of HPβCD as an excipient would not ordinarily constitute a standalone Paragraph IV case.
What generic entry risks exist for drugs using hydroxypropyl betadex?
Generic entry risk is moderate when HPβCD is used only as a conventional solubilizer and high when the formulation has difficult bioequivalence or manufacturing requirements.
Risk increases when:
- The API patent has expired.
- HPβCD is an inactive ingredient already used in approved products.
- The generic can use the same excipient grade without a novel manufacturing process.
- The drug has a straightforward oral-liquid or solution formulation.
- The formulation patent claims broad, easily designed-around parameters.
Risk decreases when:
- The formulation has a narrow concentration window.
- HPβCD controls exposure or bioavailability.
- The product is an injectable with complex dilution or stability requirements.
- The formulation requires sterile, low-endotoxin HPβCD at high loading.
- The sponsor owns validated process patents.
- The generic must demonstrate complex pharmacokinetic equivalence.
How does hydroxypropyl betadex compare with SBECD and other solubilizers?
| Attribute |
HPβCD |
SBECD |
Lipid systems |
Amorphous solid dispersions |
| Primary use |
Oral liquids, injectables, specialty formulations |
Injectable and oral solubilization |
Oral, injectable, and depot delivery |
Primarily oral solid dosage |
| Main advantage |
Strong solubilization with broad formulation flexibility |
Established parenteral use for several products |
High loading and sustained delivery options |
Suitable for commercial tablets and capsules |
| Main limitation |
High loading and route-specific safety considerations |
Cost and dose-related exposure considerations |
Physical stability and manufacturing complexity |
Reprecipitation and process sensitivity |
| Patent exposure |
Usually formulation-specific |
Product and formulation-specific |
Platform and formulation-specific |
Manufacturing and composition-specific |
| Substitution risk |
Moderate |
Moderate |
High where formulation is redesigned |
High for oral products |
No single excipient dominates all applications. HPβCD is strongest where the sponsor needs a water-based liquid and wants to avoid a more complex lipid or solid-dispersion platform.
Are there licensing deals or litigation involving hydroxypropyl betadex?
Public licensing activity is usually reported at the drug or delivery-platform level rather than as a standalone HPβCD transaction. Suppliers may provide technical licenses, confidential formulation support, or regulatory documentation without disclosing commercial terms.
There is no broadly reported, cross-market litigation proceeding that controls the commercial status of HPβCD as an excipient. Disputes are more likely to involve:
- A finished drug formulation
- A cyclodextrin manufacturing process
- Supplier quality or change control
- Contract-manufacturing obligations
- Patent claims covering a specific inclusion complex
This fragmented litigation profile reduces the value of analyzing HPβCD through a single patent-expiration date.
What is the investment and revenue exposure?
For major excipient suppliers, HPβCD is unlikely to be a separately material reported revenue segment. Its strategic value is higher than its disclosed accounting visibility because the product can support:
- Cross-selling into formulation-development projects
- Long-term supply agreements
- Regulatory dependence after product approval
- Higher-margin pharmaceutical grades
- Expansion into specialty delivery systems
Revenue concentration risk exists when a supplier depends on one or two approved products using HPβCD. A product discontinuation, generic conversion, formulation replacement, or API loss of exclusivity can reduce demand quickly.
The strongest financial position belongs to suppliers with multiple approved customers, validated global manufacturing, dual-site production, and a broader cyclodextrin portfolio. Suppliers selling only development-grade HPβCD face greater price pressure and less predictable revenue.
Key Takeaways
- HPβCD is a specialty pharmaceutical excipient used to solubilize and stabilize poorly soluble drugs.
- Itraconazole is the clearest major commercial example.
- Public sources do not provide a reliable standalone global HPβCD market size or supplier revenue breakdown.
- Growth depends on injectable, oral-liquid, pediatric, and lifecycle-management applications.
- Roquette, Wacker, CycloLab, and regional manufacturers are important suppliers.
- HPβCD has no standalone Orange Book listing or universal exclusivity date.
- Patent value generally lies in API-specific formulations, manufacturing methods, and methods of use.
- Generic risk is highest when HPβCD is a conventional inactive ingredient and the API patent has expired.
- Supplier qualification, GMP documentation, batch consistency, and regulatory support are central commercial barriers.
- HPβCD competes with SBECD, lipid systems, surfactants, cosolvents, nanocrystals, and amorphous solid dispersions.
FAQs About Hydroxypropyl Betadex
Is hydroxypropyl betadex the same as Captisol?
No. Hydroxypropyl betadex is HPβCD. Captisol is a branded form of sulfobutylether-beta-cyclodextrin, or SBECD. They have different chemical substitutions, regulatory histories, and formulation applications.
Is hydroxypropyl betadex safe for injectable drugs?
Its acceptability depends on dose, route, exposure, renal function, formulation concentration, and the specific product. Injectable use requires product-specific safety and regulatory justification.
Can a generic drug use the same hydroxypropyl betadex supplier?
Usually yes, subject to regulatory, quality, supply, and manufacturing requirements. The generic sponsor must demonstrate that the excipient grade and formulation support the required product performance.
Does hydroxypropyl betadex improve bioavailability?
It can improve apparent solubility and dissolution, which may increase or stabilize oral absorption. The effect depends on the API, complexation behavior, dose, gastrointestinal conditions, and formulation design.
Is hydroxypropyl betadex protected by composition patents?
Some specific HPβCD compositions, grades, complexes, and manufacturing processes may be patent-protected. The basic excipient concept is not equivalent to a newly patented drug substance, and protection must be assessed by patent family and jurisdiction.
References
- U.S. Food and Drug Administration. (2023). Sporanox (itraconazole) oral solution prescribing information. DailyMed.
- U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
- United States Pharmacopeia. (2024). Hydroxypropyl betadex. In United States Pharmacopeia and National Formulary.
- European Medicines Agency. (2018). Guideline on the assessment of the quality of medicinal products containing high-risk excipients.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
